Renal cell carcinoma: Should radical nephrectomy be performed in the presence of metastatic disease?

Current Opinion in Urology

Volumn 9, Issue 5, 1999, Pages 377-381

  Sawczuk, Ihor S ^a   Pollard, Jason C ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS;

EID: 0033373312     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199909000-00002     Document Type: Short Survey

References (33)

1. 1 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. 2 De Kernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978; 120:148-152.
3. 3 Montie JE, Stewart BH, Straffon RA, Banowsky LHW, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117:272-275.
4. 4 Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161:381-387. A comprehensive and clear review of present and future treatment options for metastatic RCC, including the role of radical nephrectomy.
5. 5 Atkins MB, Dutcher JP. Renal cell carcinoma. (letter) N Engl J Med 1997; 336:809.
6. 6 Umeda T, Niijima T. Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 1986; 58:1231-1235.
7. 7 Muss HB, Constanzi JJ, Leavitt R, Williams RD, Kempf RA, Pollard R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5:286-291.
8. 8 Mani S, Todd MB, Katz K, Poo W-J. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35-40.
9. 9 Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11:661-670.
10. 10 Belldegrun A, Koo AS, Bochner B, Figlin R, de Kernion JB. Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur Urol 1990; 18 (Suppl. 2):42-45.
11. 11 Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990; 144:614-618.
12. 12 Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 1992; 127:1343-1349.
13. 13 Swanson D, Markowitz A, Wishnow K, von Eschenbach A, Quesada J, Logothetis C. Primary biological therapy with delayed radical nephrectomy for patients with metastatic renal cell carcinoma [Abstract 419]. J Urol 1990; 143:293A.
14. 14 Tanguay S, Swanson DA, Putnam JB Jr. Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J Urol 1996; 156:1586-1589.
15. 15 Fleischmann JD, Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991; 145:938-941.
16. 16 Spencer WF, Linehan WM, Walther MM, Haas GP, Lotze MT, Topalian SL, et al. Immunotherapy with interleukin-2 and χ-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol 1992; 147:24-30.
17. 17 Michel K, Tso C-L, Mulders P, De Kernion J, Belldegrun A. Expression of TGFβ in renal cell carcinoma (RCC): putative role of TGF( as a tumor-infiltrating-lymphocyte (TIL) suppressor [Abstract 1473]. J Urol 1997; 157:376.
18. 18 Fincke JH, Rayman P, Kim HJ, McLain D, Sandstrom K, Novick A, et al. Impaired activation of the transcription factor NfκB in T cells from patients with renal cell carcinoma; role of cytokine therapy in modulating this defect [Abstract 1488]. J Urol 1997; 157:380.
19. 19 Whitney RB, Levy JG, Smith AG. Influence of tumor size and surgical resection on cell-mediated immunity in mice. J Natl Cancer Inst 1974; 53:111-116.
20. 20 Le Francois D, Youn JK, Belehradek J Jr, Barski G. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells. J Natl Cancer Inst 1971; 46:981-986.
21. 21 Eggermont AMM, Steller DP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lympokine-activated killer cells. Surgery 1987; 102:71-78.
22. 22 Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994; 152:1399-1403.
23. 23 Belldegrun A, Pierce W, Kaboo R, Tso C-L, Shau H, Turcillo P, et al. Interferon-χ primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-χ as therapy for metastatic renal cell carcinoma. J Urol 1993; 150:1384-1390.
24. 24 Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997; 158:1675-1678.
25. 25 Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukln-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997; 158:1691-1695.
26. 26 Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993; 42:250-258.
27. 27 Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740-745.
28. 28 Wolf JS, Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 1994; 55:7-13.
29. 29 Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154:32-34.
30. 30 Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 1998; 51:933-937. A small study that demonstrates the effectiveness of adjunctive nephrectomy performed for patients who respond to initial courses of immunotherapy.
31. 31 Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CPN. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 1998; 159:1168-1173. An important study addressing the need to define selection criteria for initial nephrectomy in order to minimize the associated morbidity and mortality that may preclude the postoperative administration of immunotherapy.
32. 32 Belldegrun A, Lange P, Thompson J, Figlin R. Aggressive surgical resection combined with low-dose RIL 2-based adoptive immunotherapy for treatment of metastatic renal cell carcinoma (MRCC); surgical biology of a large multi-center randomized placebo controlled phase II/III study [Abstract 636]. J Urol 1999; 161:165.
33. 33 Wagner JR, Rosenberg SA, Yang JC, Linehan WM, Walther MM. IL-2 based immunotherapy for metastatic renal cell carcinoma with kidney in place [Abstract 640]. J Urol 1999; 161:166.